Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lupkynis (voclosporin) is indicated for use in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis.
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Complete Remission Rate: The combination of Voclosporin (VCS) + Mycophenolate Mofetil (MMF) + Glucocorticoid (GC) achieved the highest complete remission rate among the regimens studied, with a SUCRA of 90.71%.
• Overall Response: TAC + MMF was found to have the greatest chance of being the optimal treatment for overall response (SUCRA = 0.942), outperforming VCS + MMF, which had a moderate chance (SUCRA = 0.558).
• Infection and Serious Infection Risk: VCS + MMF was associated with the highest risk of infection and serious infection when compared to other treatments, including TAC + MMF, which showed a lower risk profile.
• Other Adverse Events: No specific adverse events were reported for VCS + MMF beyond the risk of infection and serious infection. Other regimens noted included TAC + MMF, which had a higher incidence of new-onset hypertension but a lower incidence of menstrual disorders.
• There is no population types or subgroups information available in the reviewed studies.